BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
NYSE:BIO - New York Stock Exchange, Inc. - US0905722072 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to BIO. BIO was compared to 56 industry peers in the Life Sciences Tools & Services industry. While BIO has a great health rating, its profitability is only average at the moment. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
BIO had positive earnings in the past year.
In the past year BIO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
Each year in the past 5 years BIO had a positive operating cash flow.
1.2 Ratios
BIO has a Return On Assets of -19.69%. This is in the lower half of the industry: BIO underperforms 62.50% of its industry peers.
Looking at the Return On Equity, with a value of -28.07%, BIO is in line with its industry, outperforming 42.86% of the companies in the same industry.
The Return On Invested Capital of BIO (2.70%) is better than 62.50% of its industry peers.
BIO had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 12.86%.
The last Return On Invested Capital (2.70%) for BIO is above the 3 year average (2.69%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.69% | ||
| ROE | -28.07% | ||
| ROIC | 2.7% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
With a decent Operating Margin value of 11.85%, BIO is doing good in the industry, outperforming 69.64% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
BIO has a better Gross Margin (53.77%) than 62.50% of its industry peers.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.85% | ||
| PM (TTM) | N/A | ||
| GM | 53.77% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
The number of shares outstanding for BIO has been reduced compared to 1 year ago.
Compared to 5 years ago, BIO has less shares outstanding
Compared to 1 year ago, BIO has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.28 indicates that BIO is not in any danger for bankruptcy at the moment.
BIO has a better Altman-Z score (3.28) than 71.43% of its industry peers.
BIO has a debt to FCF ratio of 4.51. This is a neutral value as BIO would need 4.51 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.51, BIO is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
BIO has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
BIO's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. BIO outperforms 57.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 4.51 | ||
| Altman-Z | 3.28 |
ROIC/WACC0.27
WACC9.92%
2.3 Liquidity
A Current Ratio of 6.48 indicates that BIO has no problem at all paying its short term obligations.
BIO has a better Current ratio (6.48) than 80.36% of its industry peers.
BIO has a Quick Ratio of 4.85. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO has a Quick ratio of 4.85. This is in the better half of the industry: BIO outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.48 | ||
| Quick Ratio | 4.85 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased strongly by -12.40% in the last year.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
Looking at the last year, BIO shows a decrease in Revenue. The Revenue has decreased by -3.92% in the last year.
Measured over the past years, BIO shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-12.4%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-6.45%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-2.01%
3.2 Future
Based on estimates for the next years, BIO will show a small growth in Earnings Per Share. The EPS will grow by 2.98% on average per year.
Based on estimates for the next years, BIO will show a small growth in Revenue. The Revenue will grow by 3.30% on average per year.
EPS Next Y-5.59%
EPS Next 2Y4.86%
EPS Next 3Y5.79%
EPS Next 5Y2.98%
Revenue Next Year-0.61%
Revenue Next 2Y1.98%
Revenue Next 3Y2.81%
Revenue Next 5Y3.3%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 23.73, BIO is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of BIO indicates a somewhat cheap valuation: BIO is cheaper than 71.43% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (28.78), we can say BIO is valued inline with the index average.
BIO is valuated quite expensively with a Price/Forward Earnings ratio of 25.13.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 67.86% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.32, BIO is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.73 | ||
| Fwd PE | 25.13 |
4.2 Price Multiples
BIO's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BIO is cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.74 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.03
EPS Next 2Y4.86%
EPS Next 3Y5.79%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO (4/28/2025, 9:35:04 AM)
244.62
+1.99 (+0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners84.5%
Inst Owner Change0.17%
Ins Owners3.65%
Ins Owner Change0%
Market Cap6.85B
Analysts76.36
Price Target356.83 (45.87%)
Short Float %3.67%
Short Ratio1.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.08%
Min EPS beat(2)0.1%
Max EPS beat(2)72.05%
EPS beat(4)4
Avg EPS beat(4)32.67%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)6
Avg EPS beat(8)15.85%
EPS beat(12)8
Avg EPS beat(12)14.81%
EPS beat(16)12
Avg EPS beat(16)21.47%
Revenue beat(2)1
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)2.41%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)2.41%
Revenue beat(8)1
Avg Revenue beat(8)-2.72%
Revenue beat(12)3
Avg Revenue beat(12)-1.86%
Revenue beat(16)6
Avg Revenue beat(16)0.6%
PT rev (1m)-5.32%
PT rev (3m)-12.4%
EPS NQ rev (1m)-1.88%
EPS NQ rev (3m)-32.27%
EPS NY rev (1m)-0.29%
EPS NY rev (3m)-16.3%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-9.12%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-3.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.73 | ||
| Fwd PE | 25.13 | ||
| P/S | 2.67 | ||
| P/FCF | 25.74 | ||
| P/OCF | 15.05 | ||
| P/B | 1.04 | ||
| P/tB | 1.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY4.21%
EPS(NY)9.73
Fwd EY3.98%
FCF(TTM)9.5
FCFY3.89%
OCF(TTM)16.25
OCFY6.64%
SpS91.63
BVpS234.53
TBVpS209.4
PEG (NY)N/A
PEG (5Y)3.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.69% | ||
| ROE | -28.07% | ||
| ROCE | 3.42% | ||
| ROIC | 2.7% | ||
| ROICexc | 3.32% | ||
| ROICexgc | 3.68% | ||
| OM | 11.85% | ||
| PM (TTM) | N/A | ||
| GM | 53.77% | ||
| FCFM | 10.37% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 4.51 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.36% | ||
| Interest Coverage | -6.54 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.48 | ||
| Quick Ratio | 4.85 | ||
| Altman-Z | 3.28 |
F-Score6
WACC9.92%
ROIC/WACC0.27
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.4%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-6.45%
EPS Next Y-5.59%
EPS Next 2Y4.86%
EPS Next 3Y5.79%
EPS Next 5Y2.98%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-2.01%
Revenue Next Year-0.61%
Revenue Next 2Y1.98%
Revenue Next 3Y2.81%
Revenue Next 5Y3.3%
EBIT growth 1Y-16.75%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year39.02%
EBIT Next 3Y17.83%
EBIT Next 5Y14.69%
FCF growth 1Y21.96%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y21.41%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%